These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
479 related articles for article (PubMed ID: 32144135)
41. Survival of Patients with Deficient Mismatch Repair Versus Proficient Mismatch Repair Metastatic Colorectal Cancer Receiving Curative-Intent Local Treatment of Metastases in a Nationwide Cohort. Zwart K; van der Baan FH; Punt CJA; Wensink GE; Bolhuis K; Laclé MM; van Grevenstein WMU; Hagendoorn J; de Hingh IH; Koopman M; Vink G; Roodhart J Ann Surg Oncol; 2023 Oct; 30(11):6762-6770. PubMed ID: 37528303 [TBL] [Abstract][Full Text] [Related]
42. Rationale for evaluating breast cancers of Lynch syndrome patients for mismatch repair gene expression. Sorscher S Breast Cancer Res Treat; 2019 Nov; 178(2):469-471. PubMed ID: 31392519 [TBL] [Abstract][Full Text] [Related]
43. Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations. Li W; Zhi W; Zou S; Qiu T; Ling Y; Shan L; Shi S; Ying J PLoS One; 2015; 10(6):e0128202. PubMed ID: 26042813 [TBL] [Abstract][Full Text] [Related]
44. The implications of BRCA loss of heterozygosity (LOH) and deficient mismatch repair gene (dMMR) expression in the breast cancer of a patient with both inherited breast and ovarian cancer syndrome (BRCA2) and Lynch syndrome (MLH1). Sorscher S; Ansley K; Delaney SD; Ramkissoon S Breast Cancer Res Treat; 2020 Apr; 180(2):511-514. PubMed ID: 32040686 [TBL] [Abstract][Full Text] [Related]
45. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Koopman M; Kortman GA; Mekenkamp L; Ligtenberg MJ; Hoogerbrugge N; Antonini NF; Punt CJ; van Krieken JH Br J Cancer; 2009 Jan; 100(2):266-73. PubMed ID: 19165197 [TBL] [Abstract][Full Text] [Related]
46. [Association of status of mismatch repair protein expression and EB virus infection with clinicopathological parameters in 886 gastric adenocarcinoma patients]. Liu Y; Zang FL; Qiu ZQ; Guo YH; Luo Y; Sun L; Zhao S; Shao B; Liang H; Sun Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):440-448. PubMed ID: 34000774 [No Abstract] [Full Text] [Related]
47. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. French AJ; Sargent DJ; Burgart LJ; Foster NR; Kabat BF; Goldberg R; Shepherd L; Windschitl HE; Thibodeau SN Clin Cancer Res; 2008 Jun; 14(11):3408-15. PubMed ID: 18519771 [TBL] [Abstract][Full Text] [Related]
48. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy. Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397 [TBL] [Abstract][Full Text] [Related]
49. Screening for germline mutations of MLH1, MSH2, MSH6 and PMS2 genes in Slovenian colorectal cancer patients: implications for a population specific detection strategy of Lynch syndrome. Berginc G; Bracko M; Ravnik-Glavac M; Glavac D Fam Cancer; 2009; 8(4):421-9. PubMed ID: 19526325 [TBL] [Abstract][Full Text] [Related]
50. Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer. Oh CR; Kim EJ; Chae H; Park YS; Ryu MH; Kim HD; Kang YK Gastric Cancer; 2024 Jul; 27(4):811-818. PubMed ID: 38555561 [TBL] [Abstract][Full Text] [Related]
51. A relationship to survival is seen by combining the factors of mismatch repair status, tumor location and age of onset in colorectal cancer patients. Li P; Xiao Z; Braciak TA; Ou Q; Chen G; Oduncu FS PLoS One; 2017; 12(3):e0172799. PubMed ID: 28253296 [TBL] [Abstract][Full Text] [Related]
52. Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial. Antill Y; Kok PS; Robledo K; Yip S; Cummins M; Smith D; Spurdle A; Barnes E; Lee YC; Friedlander M; Baron-Hay S; Shannon C; Coward J; Beale P; Goss G; Meniawy T; Lombard J; Andrews J; Stockler MR; Mileshkin L; J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103352 [TBL] [Abstract][Full Text] [Related]
53. Clinical Targeted Next-Generation Sequencing Shows Increased Mutational Load in Endometrioid-type Endometrial Adenocarcinoma With Deficient DNA Mismatch Repair. Lee PJ; McNulty S; Duncavage EJ; Heusel JW; Hagemann IS Int J Gynecol Pathol; 2018 Nov; 37(6):581-589. PubMed ID: 29084048 [TBL] [Abstract][Full Text] [Related]
54. Lynch syndrome identification in a Brazilian cohort of endometrial cancer screened by a universal approach. Rosa RCA; Santis JO; Teixeira LA; Molfetta GA; Dos Santos JTT; Ribeiro VDS; Chahud F; Ribeiro-Silva A; Brunaldi MO; Silva WA; Ferraz VEF Gynecol Oncol; 2020 Oct; 159(1):229-238. PubMed ID: 32694065 [TBL] [Abstract][Full Text] [Related]
55. Elucidating the molecular basis of MSH2-deficient tumors by combined germline and somatic analysis. Vargas-Parra GM; González-Acosta M; Thompson BA; Gómez C; Fernández A; Dámaso E; Pons T; Morak M; Del Valle J; Iglesias S; Velasco À; Solanes A; Sanjuan X; Padilla N; de la Cruz X; Valencia A; Holinski-Feder E; Brunet J; Feliubadaló L; Lázaro C; Navarro M; Pineda M; Capellá G Int J Cancer; 2017 Oct; 141(7):1365-1380. PubMed ID: 28577310 [TBL] [Abstract][Full Text] [Related]
56. Correlation between mismatch repair and survival of patients with gastric cancer after 5-FU-based adjuvant chemotherapy. Zhao F; Li E; Shen G; Dong Q; Ren D; Wang M; Zhao Y; Liu Z; Ma J; Xie Q; Liu Z; Li Z; Gao L; Zhao J J Gastroenterol; 2023 Jul; 58(7):622-632. PubMed ID: 37036516 [TBL] [Abstract][Full Text] [Related]
57. Survival outcomes in locally advanced dMMR rectal cancer: surgery plus adjunctive treatment vs. surgery alone. Ni K; Zhan Y; Liu Z; Yuan Z; Wang S; Zhao XZ; Ping H; Liu Y; Wang W; Yan S; Xin R; Han Q; Zhang Q; Li G; Zhang X; Wang G; Zhang Z; Ma H; Zhang C BMC Cancer; 2023 Oct; 23(1):1013. PubMed ID: 37864137 [TBL] [Abstract][Full Text] [Related]
58. Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer. Kim JE; Hong YS; Ryu MH; Lee JL; Chang HM; Lim SB; Kim JH; Jang SJ; Kim MJ; Yu CS; Kang YK; Kim JC; Kim TW Cancer Sci; 2011 Sep; 102(9):1706-11. PubMed ID: 21679278 [TBL] [Abstract][Full Text] [Related]
59. Oral squamous cell cancer in a patient with Lynch syndrome. Sorscher S; Lycan T Oral Oncol; 2019 Oct; 97():137-138. PubMed ID: 31445773 [TBL] [Abstract][Full Text] [Related]
60. Comprehensive analysis of DNA mismatch repair-deficient gastric cancer in a Japanese hospital-based population. Ito T; Suzuki O; Kamae N; Tamaru JI; Arai T; Yamaguchi T; Akagi K; Eguchi H; Okazaki Y; Mochiki E; Ishida H Jpn J Clin Oncol; 2021 May; 51(6):886-894. PubMed ID: 33728435 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]